Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 8/20 | 0.64 |
| ▸ | MET | P08581 | 6/20 | 0.57 |
| ▸ | HRH4 | Q9H3N8 | 5/20 | 0.52 |
| ▸ | HTR3A | P46098 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14237703 | 0.85 | TLR9 (0.64) | TLR9METHRH4HTR3A | |
| SCHEMBL14238531 | 0.80 | TLR9 (0.62) | TLR9HRH4HTR3APOLBHTT | |
| SCHEMBL15581723 | 0.78 | TLR9 (1.00) | TLR9MET | |
| SCHEMBL14237940 | 0.78 | TLR9 (1.00) | TLR9METHRH4HTR3A | |
| SCHEMBL14237881 | 0.75 | TLR9 (1.00) | TLR9MET | |
| SCHEMBL29161384 | 0.74 | CKS1B (0.68) | METHRH4HTR3A | |
| SCHEMBL14237542 | 0.74 | TLR9 (1.00) | TLR9METHRH4 | |
| SCHEMBL14238171 | 0.74 | TLR9 (0.87) | TLR9 | |
| SCHEMBL14238632 | 0.74 | TLR9 (1.00) | TLR9METHRH4 | |
| SCHEMBL14237768 | 0.74 | TLR9 (1.00) | TLR9METHRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2713736-B1 | NOVEL IMMUNE SYSTEM MODULATORS | JANUS BIOTHERAPEUTICS INC (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20170224699-A1 | NOVEL IMMUNE SYSTEM MODULATORS | Wilmer Cutler Pickering Hale and Dorr LLP | 2017-08-10 | — | — | US | disclosed |
| US-20170224699-A1 | NOVEL IMMUNE SYSTEM MODULATORS | Wilmer Cutler Pickering Hale and Dorr LLP | 2017-08-10 | — | — | US | disclosed |
| US-9637489-B2 | Immune system modulators | JANUS BIOTHERAPEUTICS, INC. (US) | 2017-05-02 | — | — | US | disclosed |
| US-9637489-B2 | Immune system modulators | JANUS BIOTHERAPEUTICS, INC. (US) | 2017-05-02 | — | — | US | disclosed |
| US-9359361-B2 | Immune system modulators | JANUS BIOTHERAPEUTICS, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-9359361-B2 | Immune system modulators | JANUS BIOTHERAPEUTICS, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-20160074403-A1 | NOVEL IMMUNE SYSTEM MODULATORS | Wilmer Cutler Pickering Hale and Dorr LLP | 2016-03-17 | — | — | US | disclosed |
| US-20160074403-A1 | NOVEL IMMUNE SYSTEM MODULATORS | Wilmer Cutler Pickering Hale and Dorr LLP | 2016-03-17 | — | — | US | disclosed |
| US-9126996-B2 | Immune system modulators | JANUS BIOTHERAPEUTICS, INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-9126996-B2 | Immune system modulators | JANUS BIOTHERAPEUTICS, INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-20140221646-A1 | NOVEL IMMUNE SYSTEM MODULATORS | JANUS BIOTHERAPEUTICS, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221646-A1 | NOVEL IMMUNE SYSTEM MODULATORS | JANUS BIOTHERAPEUTICS, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140079724-A1 | NOVEL IMMUNE SYSTEM MODULATORS | JANUS BIOTHERAPEUTICS, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-20140079724-A1 | NOVEL IMMUNE SYSTEM MODULATORS | JANUS BIOTHERAPEUTICS, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| WO-2012167046-A1 | NOVEL IMMUNE SYSTEM MODULATORS | JANUS BIOTHERAPEUTICS, INC. (US) | 2012-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140079724-A1 | NOVEL IMMUNE SYSTEM MODULATORS | HLA-DRB1, CD47, MYD88 | TLR9 19/4885MET 3113/4885HRH4 725/4885 |
| US-20140221646-A1 | NOVEL IMMUNE SYSTEM MODULATORS | HLA-DRB1, CD47, MYD88 | TLR9 19/4885MET 3113/4885HRH4 725/4885 |
| US-20160074403-A1 | NOVEL IMMUNE SYSTEM MODULATORS | HLA-DRB1, CD47, MYD88 | TLR9 19/4885MET 3113/4885HRH4 725/4885 |
| US-20170224699-A1 | NOVEL IMMUNE SYSTEM MODULATORS | HLA-DRB1, CD47, MYD88 | TLR9 19/4885MET 3113/4885HRH4 725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.